Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;67(1):26-28.
doi: 10.3164/jcbn.20-51. Epub 2020 Jun 5.

Nutrients and probiotics: current trends in their use to eradicate Helicobacter pylori

Osamu Handa  1   2 , Yuji Naito  2 , Motoyasu Osawa  1 , Takahisa Murao  1 , Hiroshi Matsumoto  1 , Eiji Umegaki  1 , Akiko Shiotani  1
Affiliations
Review

Nutrients and probiotics: current trends in their use to eradicate Helicobacter pylori

Osamu Handa et al. J Clin Biochem Nutr. 2020 Jul.

Abstract

Helicobacter pylori is a well-known bacterium that infects the human gastric mucosa and causes gastric inflammation, ultimately resulting in gastric cancer. To reduce the incidence of gastric cancer, eradication therapy is important. However, the rate of successful eradication gradually decreases due to increased antibiotic resistance to Helicobacter pylori. In order to increase the eradication rate and reduce gastric cancer incidence, food factors or probiotics are expected to play a beneficial role. Although several foods have been reported to inhibit bacterial load and gastric inflammation, further assessment on large population prospective studies in this field is warranted. Several food compounds, including phytochemicals, are reported to suppress the incidence of gastric cancer. Future evaluations should consider differences in geographic factors. Probiotics are effective and safe for use in Helicobacter pylori eradication therapy.

Keywords: Helicobacter pylori; cancer chemoprevention; food factors; probiotics.

PubMed Disclaimer

Conflict of interest statement

YN received a scholarship fund from EA Pharma. Co. Ltd. and collaboration research fund from FUJIFILM Medical Co. Ltd. and Taiyo Kagaku Co., Ltd., and has been paid lecture fees by Mylan EPD Co., Takeda Pharma. Co. Ltd., Mochida Pharma. Co. Ltd., EA Pharma. Co. Ltd., Otsuka Pharma. Co. Ltd., Nippon Kayaku Co. Ltd., and Miyarisan Pharma. Co. Ltd. The present research was partly funded by these funds. Neither the funding agency nor any outside organization has participated in study design or have any competing of interest. AS received a scholarship fund from Takeda Pharma. Co. Ltd., Mochida Pharma. Co. Ltd., and Daiichi-Sankyo Pharma. Co. Ltd. and collaboration research fund from AstraZeneca Co. Ltd. And has been paid lecture fees by Takeda Pharma. Co. Ltd., and Astellas Pharma. Co. Ltd. The present research was partly funded by these funds. Neither the funding agency nor any outside organization has participated in study design or have any competing of interest.

Figures

Fig. 1
Fig. 1
Phytochemicals.
See this image and copyright information in PMC

References

    1. Handa O, Naito Y, Yoshikawa T. Helicobacter pylori: a ROS-inducing bacterial species in the stomach. Inflamm Res 2010; 59: 997–1003. - PubMed
    1. Kato M, Ota H, Okuda M et al. . Guidelines for the management of Helicobacter pylori infection in Japan: 2016 revised edition. Helicobacter 2019; 24: e12597. - PubMed
    1. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784–789. - PubMed
    1. Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2019; 22: 435–445. - PubMed
    1. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143–1153. - PubMed